WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
920 Views
WuXi Biologics: Updated Valuation Data
We have heard that WuXi Biologics' bankers are preparing to move forward with the offering though a PHIP has not been posted yet. Â The updated...
838 Views
Samsung Restructuring Update - Newly Emerging Scenario & Regulatory Pushes
Samsung restructuring debate doesn't really seem to have ended. Among Korea's local investors, this just continues to be one of the topics that are...
368 Views
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
706 Views
Reconsider the Samsung Bioepis Valuation
As noted in our Insight Pass on the Deal, Put on the Watchlist one of the underpinnings of the valuation of Samsung Biologics Co., Ltd (207940 KS)...
877 Views